[{"id":"d393c421-1cb3-4ec6-9581-ed088473191d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762069","created_at":"2021-02-21T13:52:16.258Z","updated_at":"2024-07-02T16:35:37.087Z","phase":"Phase 2","brief_title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","source_id_and_acronym":"NCT04762069","lead_sponsor":"CNS Pharmaceuticals, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • lomustine • berubicin (RTA 744)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/18/2021","start_date":" 05/18/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-09-13"}]